{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:43:50Z","timestamp":1792748630188,"version":"4.5.0"},"reference-count":64,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1307504"],"award-info":[{"award-number":["2024YFA1307504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Project in Guangzhou"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22477043"],"award-info":[{"award-number":["22477043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273763"],"award-info":[{"award-number":["82273763"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004024","name":"Jinan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2025A0505020049"],"award-info":[{"award-number":["2025A0505020049"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024B1515040007"],"award-info":[{"award-number":["2024B1515040007"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018621","name":"Program for Changjiang Scholars and Innovative Research Team in University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Covalent kinase inhibitors (CKIs) serve as potent therapeutics, yet their development largely depends on conserved cysteine residues. Many kinases lack accessible cysteines or develop resistance mutations at these sites, limiting clinical utility. To diversify targetable nucleophilic amino acids, we developed a modular strategy for arginine reactive CKIs using two warhead types: O-cyanobenzaldehyde (CNBA) and phenylglyoxal (PGO). We first synthesized RA2, a CNBA-based AURKA inhibitor targeting arginine (R220), which showed weak cellular activity (GI50 &amp;gt; 2 \u03bcM). Using PGO warhead, we generated covalent inhibitors C1 against ALK-G1202R and L1a against TRKA-G595R; both strongly inhibited arginine-mutant kinases but showed unsatisfactory cellular potency. Further optimization of PGO electrophilicity via methoxy substitution yielded L1c, which exhibited potent cellular activity (GI50 = 0.39 \u03bcM) against drug-resistant Ba\/F3-CD74-TRKA-G595R cells and sustained target engagement. Collectively, this work expands the CKI toolbox to include arginine-targeting warheads and provides a modular framework to overcome point mutation-driven resistance.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01581","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:03:19Z","timestamp":1790179399000},"page":"24010-24029","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of Arginine-Reactive Covalent Kinase Inhibitors Overcoming Clinical Drug Resistance"],"prefix":"10.1021","volume":"69","author":[{"given":"Zuqin","family":"Wang","sequence":"first","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]},{"name":"The Affiliated Guangdong Second Provincial General Hospital of Jinan University , , , ,","place":["Guangzhou, Guangdong Province, China, 510317"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahuan","family":"He","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4044-5488","authenticated-orcid":true,"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ling","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[{"name":"National University of Singapore , , ,","place":["Singapore, Singapore, 117543"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibo","family":"Kang","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Song","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengchao","family":"Tu","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-9699","authenticated-orcid":true,"given":"Zhang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-5869","authenticated-orcid":true,"given":"Zhi-Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4715-769X","authenticated-orcid":true,"given":"Shao Q.","family":"Yao","sequence":"additional","affiliation":[{"name":"National University of Singapore , , ,","place":["Singapore, Singapore, 117543"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7931-6873","authenticated-orcid":true,"given":"Xiaoyun","family":"Lu","sequence":"additional","affiliation":[{"name":"Jinan University , , #855 Xingye Avenue , ,","place":["Guangzhou, China, 510632"]},{"name":"The Affiliated Guangdong Second Provincial General Hospital of Jinan University , , , ,","place":["Guangzhou, Guangdong Province, China, 510317"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"19","key":"2026102305074206400_cit1","doi-asserted-by":"publisher","first-page":"10726","DOI":"10.1021\/acs.jmedchem.0c00507","article-title":"Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026102305074206400_cit2","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1039\/c9cs00720b","article-title":"Advances in covalent kinase inhibitors","volume":"49","author":"Abdeldayem","year":"2020","journal-title":"Chem. Soc. Rev."},{"issue":"9","key":"2026102305074206400_cit3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.cd-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"20","key":"2026102305074206400_cit4","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026102305074206400_cit5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"2026102305074206400_cit6","doi-asserted-by":"publisher","first-page":"107805","DOI":"10.1016\/j.phrs.2025.107805","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update","volume":"217","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"12","key":"2026102305074206400_cit7","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1039\/d2md00216g","article-title":"Advanced approaches of developing targeted covalent drugs","volume":"13","author":"Gai","year":"2022","journal-title":"RSC Med. Chem."},{"issue":"24","key":"2026102305074206400_cit8","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/nejmoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"2026102305074206400_cit9","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"30","key":"2026102305074206400_cit10","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1002\/anie.201802693","article-title":"Reactive Chemical Probes: Beyond the Kinase Cysteinome","volume":"57","author":"Jones","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"2026102305074206400_cit11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/bs.armc.2020.10.001","article-title":"Design of next-generation covalent inhibitors: Targeting residues beyond cysteine","volume":"56","author":"Jones","year":"2020","journal-title":"Annu. Rep. Med. Chem."},{"issue":"50","key":"2026102305074206400_cit12","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202515603","article-title":"Quantitative Reactivity Profiling of Functional Arginine Residues in Human Cancer Cell Line Proteomes","volume":"137","author":"Zhao","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"2026102305074206400_cit13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41557-025-02012-6","article-title":"Global profiling of arginine reactivity and ligandability in the human proteome.","volume":"18","author":"Wang","year":"2026","journal-title":"Nat. Chem."},{"issue":"1","key":"2026102305074206400_cit14","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1038\/s41467-019-11917-z","article-title":"Improving mass spectrometry analysis of protein structures with arginine-selective chemical cross-linkers","volume":"10","author":"Jones","year":"2019","journal-title":"Nat. Commun."},{"issue":"35","key":"2026102305074206400_cit15","doi-asserted-by":"publisher","first-page":"15916","DOI":"10.1021\/jacs.2c05377","article-title":"Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile","volume":"144","author":"Zhang","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"2026102305074206400_cit16","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1021\/acs.jmedchem.4c00078","article-title":"Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3K\u03b1 Mutant Protein","volume":"67","author":"Ketcham","year":"2024","journal-title":"J. Med. Chem."},{"issue":"17","key":"2026102305074206400_cit17","doi-asserted-by":"publisher","first-page":"14702","DOI":"10.1021\/acs.jmedchem.4c00361","article-title":"Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026102305074206400_cit18","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/s0959-8049(16)33009-x","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"69","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"issue":"2","key":"2026102305074206400_cit19","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"2026102305074206400_cit20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cancergen.2021.12.002","article-title":"NTRK point mutations and their functional consequences","volume":"262\u2212263","author":"Rogers","year":"2022","journal-title":"Cancer Genet."},{"issue":"25","key":"2026102305074206400_cit21","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/nejmoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"2026102305074206400_cit22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"2026102305074206400_cit23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.cd-20-0487","article-title":"Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain","volume":"11","author":"Grunewald","year":"2021","journal-title":"Cancer Discov."},{"issue":"8","key":"2026102305074206400_cit24","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1021\/acs.jmedchem.2c00308","article-title":"Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"18","key":"2026102305074206400_cit25","doi-asserted-by":"publisher","first-page":"12950","DOI":"10.1021\/acs.jmedchem.3c00899","article-title":"Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026102305074206400_cit26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.cd-16-1237","article-title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"16","key":"2026102305074206400_cit27","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1002\/anie.201707875","article-title":"The Cysteinome of Protein Kinases as a Target in Drug Development","volume":"57","author":"Chaikuad","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"issue":"3","key":"2026102305074206400_cit28","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1021\/acs.jmedchem.0c01707","article-title":"Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design","volume":"64","author":"Yan","year":"2021","journal-title":"J. Med. Chem."},{"issue":"26","key":"2026102305074206400_cit29","doi-asserted-by":"publisher","first-page":"18492","DOI":"10.1074\/jbc.274.26.18492","article-title":"Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts","volume":"274","author":"Oya","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"23","key":"2026102305074206400_cit30","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1016\/s0021-9258(18)94475-3","article-title":"The reaction of phenylglyoxal with arginine residues in proteins","volume":"243","author":"Takahashi","year":"1968","journal-title":"J. Biol. Chem."},{"issue":"2","key":"2026102305074206400_cit31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/oxfordjournals.jbchem.a131472","article-title":"Further studies on the reactions of phenylglyoxal and related reagents with proteins","volume":"81","author":"Takahashi","year":"1977","journal-title":"J. Biochem."},{"issue":"3","key":"2026102305074206400_cit32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0045-2068(91)90049-u","article-title":"Exploring arylglyoxals as the arginine reactivity probes. A mechanistic investigation using the buffer and substituent effects","volume":"19","author":"Baburaj","year":"1991","journal-title":"Bioorg. Chem."},{"issue":"11","key":"2026102305074206400_cit33","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1021\/acs.bioconjchem.4c00317","article-title":"A Diketopinic Reagent for the Reversible Bioconjugation to Arginine Residues on Native Antibodies","volume":"35","author":"Bertelsen","year":"2024","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"2026102305074206400_cit34","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/ja01008a056","article-title":"A simple trimerization of 2,3-butanedione yielding a selective reagent for the modification of arginine in proteins","volume":"90","author":"Yankeelov","year":"1968","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"2026102305074206400_cit35","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1016\/s0021-9258(19)45268-x","article-title":"Modification of an arginyl residue in pepsin by 2,3-butanedione","volume":"247","author":"Huang","year":"1972","journal-title":"J. Biol. Chem."},{"issue":"12","key":"2026102305074206400_cit36","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1073\/pnas.89.12.5630","article-title":"Protein surface topology-probing by selective chemical modification and mass spectrometric peptide mapping","volume":"89","author":"Suckau","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"2026102305074206400_cit37","doi-asserted-by":"publisher","first-page":"10139","DOI":"10.1021\/jacs.4c14476","article-title":"Chemical Carbonylation of Arginine in Peptides and Proteins","volume":"147","author":"Prosser","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"25","key":"2026102305074206400_cit38","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1021\/acs.orglett.2c01970","article-title":"Dibenzocyclooctendiones (DBCDOs): Arginine-Selective Chemical Labeling Reagents Obtained through Benzilic Acid Rearrangement","volume":"24","author":"Shih","year":"2022","journal-title":"Org. Lett."},{"issue":"8","key":"2026102305074206400_cit39","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/c7ob02844j","article-title":"Arginine-selective bioconjugation with 4-azidophenyl glyoxal: application to the single and dual functionalisation of native antibodies","volume":"16","author":"Dovgan","year":"2018","journal-title":"Org. Biomol. Chem."},{"issue":"1","key":"2026102305074206400_cit40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.aca.2008.05.074","article-title":"Nested Arg-specific bifunctional crosslinkers for MS-based structural analysis of proteins and protein assemblies","volume":"627","author":"Zhang","year":"2008","journal-title":"Anal. Chim. Acta"},{"issue":"11","key":"2026102305074206400_cit41","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41557-025-01902-z","article-title":"Profiling the proteome-wide selectivity of diverse electrophiles","volume":"17","author":"Zanon","year":"2025","journal-title":"Nat. Chem."},{"issue":"41","key":"2026102305074206400_cit42","doi-asserted-by":"publisher","first-page":"17015","DOI":"10.1021\/ja308871v","article-title":"Seeing citrulline: development of a phenylglyoxal-based probe to visualize protein citrullination","volume":"134","author":"Bicker","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"2026102305074206400_cit43","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202422372","article-title":"Cell-Active, Arginine-Targeting Irreversible Covalent Inhibitors for Non-Kinases and Kinases","author":"Chen","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"2026102305074206400_cit44","doi-asserted-by":"publisher","first-page":"11955","DOI":"10.1021\/jacs.4c18006","article-title":"O-Cyanobenzaldehydes Irreversibly Modify Both Buried and Exposed Lysine Residues in Live Cells","volume":"147","author":"Ling","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"14","key":"2026102305074206400_cit45","doi-asserted-by":"publisher","first-page":"23937","DOI":"10.18632\/oncotarget.14893","article-title":"Aurora kinases: novel therapy targets in cancers","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"key":"2026102305074206400_cit46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: a comprehensive review","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Div."},{"key":"2026102305074206400_cit47","doi-asserted-by":"publisher","first-page":"113495","DOI":"10.1016\/j.ejmech.2021.113495","article-title":"Aurora kinase inhibitors as potential anticancer agents: Recent advances","volume":"221","author":"Pradhan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"2026102305074206400_cit48","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40265-014-0251-3","article-title":"Ceritinib: first global approval","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"issue":"6","key":"2026102305074206400_cit49","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/2159-8290.cd-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"issue":"24","key":"2026102305074206400_cit50","doi-asserted-by":"publisher","first-page":"8288","DOI":"10.1039\/d1sc01359a","article-title":"Recent advances in activity-based probes (ABPs) and affinity-based probes (AfBPs) for profiling of enzymes","volume":"12","author":"Fang","year":"2021","journal-title":"Chem. Sci."},{"issue":"2","key":"2026102305074206400_cit51","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: First Global Approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"issue":"9","key":"2026102305074206400_cit52","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1158\/2159-8290.cd-17-0507","article-title":"A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"10","key":"2026102305074206400_cit53","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/2159-8290.cd-18-0484","article-title":"Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent- Front Mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"issue":"6","key":"2026102305074206400_cit54","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1021\/ml500409n","article-title":"MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors","volume":"6","author":"Sells","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"42","key":"2026102305074206400_cit55","doi-asserted-by":"publisher","first-page":"7733","DOI":"10.1002\/anie.201003009","article-title":"Synthesis of aryl ketones by palladium(II)-catalyzed decarboxylative addition of benzoic acids to nitriles","volume":"49","author":"Lindh","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"issue":"11","key":"2026102305074206400_cit56","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nbt.4236","article-title":"Comprehensive identification of peptides in tandem mass spectra using an efficient open search engine","volume":"36","author":"Chi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"2026102305074206400_cit57","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1107\/s0907444906019949","article-title":"HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes","volume":"62","author":"Minor","year":"2006","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"4","key":"2026102305074206400_cit58","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/s0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"issue":"4","key":"2026102305074206400_cit59","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/s0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta. Crystallogr. D. Biol. Crystallogr."},{"issue":"10","key":"2026102305074206400_cit60","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/s2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallogr. D. Struct. Biol."},{"issue":"19","key":"2026102305074206400_cit61","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.3390\/molecules27196500","article-title":"JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"issue":"12","key":"2026102305074206400_cit62","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202316394","article-title":"Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development","volume":"136","author":"Tang","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"issue":"34","key":"2026102305074206400_cit63","doi-asserted-by":"publisher","first-page":"23978","DOI":"10.1021\/jacs.4c07181","article-title":"Small Molecule-Induced Post-Translational Acetylation of Catalytic Lysine of Kinases in Mammalian Cells","volume":"146","author":"Tang","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"40","key":"2026102305074206400_cit64","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202510763","article-title":"Cell-Active, Irreversible Covalent Inhibitors Targeting a Surface-Exposed Non-Catalytic Lysine on Aurora a Kinase by Using Squarate Chemistry","volume":"137","author":"Wang","year":"2025","journal-title":"Angew. Chem. Int. Ed."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01581","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24010\/68625172\/jm6c01581.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24010\/68625172\/jm6c01581.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:25:13Z","timestamp":1792747513000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/24010\/5436868\/Discovery-of-Arginine-Reactive-Covalent-Kinase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":64,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01581","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}